Methylmalonic Acid

Methylmalonic Acid

SCHEMBL106056

CC(C(=O)[O-])C(=O)[O-].[K+].[K+]

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Methylmalonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CA4 P22748 3/20 0.44
CA1 P00915 6/20 0.40
FAHD1 Q6P587 1/20 0.40
CA2 P00918 1/20 0.38
CYP3A4 P08684 2/20 0.36
TSHR P16473 2/20 0.36
NFKB1 P19838 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TP53 P04637 1/20 0.33
MEN1 O00255 1/20 0.33
LDHA P00338 1/20 0.33
BLM P54132 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylmalonic Acid SCHEMBL21270021 0.96 CA4 (0.41) CA4CA1FAHD1CA2CYP3A4
Methylmalonic Acid SCHEMBL21269694 0.96 CA4 (0.47) CA4CA1FAHD1CA2CYP3A4
Methylmalonic Acid SCHEMBL108312 0.96
Methylmalonic Acid SCHEMBL29072904 0.96 CA4 (0.41) CA4CA1FAHD1CA2CYP3A4
Methylmalonic Acid SCHEMBL11586864 0.92
Methylmalonic Acid SCHEMBL21269785 0.92
Methylmalonic Acid SCHEMBL17818675 0.92 CA1 (0.40) CA4CA1CA2CYP3A4TSHR
Methylmalonic Acid SCHEMBL5622821 0.92 CA1 (0.40) CA4CA1CA2CYP3A4TSHR
Methylmalonic Acid SCHEMBL17818679 0.92
Methylmalonic Acid SCHEMBL9468796 0.92

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118320360-A Easily-decomposed high-performance fire extinguishing coolant for aerosol fire extinguishing agent 湖北及安盾消防科技有限公司 2024-07-12 CN claimed
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION LIMITED (IN) 2019-08-22 US claimed
EP-3527616-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION Ltd. (IN) 2019-08-21 EP claimed
EP-1878493-B1 Method of making a polyisocyanurate/polyurethane foam using carbocation compounds as trimerization catalysts AIR PROD & CHEM (US) 2013-08-21 EP claimed
US-20080161560-A1 Process for Preparation of Calcium Salt of Rosuvastatin DESHPANDE PANDURANG BALWANT 2008-07-03 US claimed
EP-1869005-A1 PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN UNICHEM LABORATORIES LIMITED (IN) 2007-12-26 EP claimed
WO-2006106526-A1 PROCESS FOR PREPARATION OF CALCIUM SALT OF ROSUVASTATIN UNICHEM LABORATORIES LIMITED (IN) 2006-10-12 WO claimed
EP-0652213-B1 Method for producing alkyl 3-phthalidylideneacetate SUMIKA FINE CHEMICALS CO LTD (JP) 1997-08-27 EP claimed
US-4200586-A Inhibiting the carbon-carbon double bond isomerization of substituted or unsubstituted hydrocarbon compounds PHILLIPS PETROLEUM COMPANY (US) 1980-04-29 US claimed
WO-2026103793-A1 TRICYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-21 WO disclosed
CN-120077048-A Tricyclic compounds and uses thereof 诺华股份有限公司 2025-05-30 CN disclosed
EP-4554569-A1 AGENT CONTAINING MALONIC ACID OR ITS DERIVATIVES FOR RESTORING METAL HOMEOSTASIS Oxford Antibiotic Group GmbH (AT) 2025-05-21 EP disclosed
CN-119866217-A Agent for restoring metal steady state containing malonic acid or derivative thereof 牛津抗生素(制药)集团股份有限公司 2025-04-22 CN disclosed
CN-114616226-B Pyridine derivatives as TMEM16A modulators for the treatment of respiratory disorders TMEM16A有限公司 2025-03-04 CN disclosed
EP-0950653-A1 Process for the preparation of potassium monoethylmalonate CREANOVA Spezialchemie GmbH (DE) 1999-10-20 EP disclosed
WO-1999012892-A1 SUBSTITUTED ALKENOIC ACIDS AND THEIR DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1999-03-18 WO disclosed
WO-1999012885-A1 SUBSTITUTED ALKENOIC ACIDS AND THEIR DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 1999-03-18 WO disclosed
US-5849749-A 6-(hydroxymethyl-ethyl)pyridines BAYER AKTIENGESELLSCHAFT (DE) 1998-12-15 US disclosed
US-4200586-A Inhibiting the carbon-carbon double bond isomerization of substituted or unsubstituted hydrocarbon compounds PHILLIPS PETROLEUM COMPANY (US) 1980-04-29 US disclosed
US-4169846-A ANTITUMOR AGENTS INAGAKI KENJI (JP) 1979-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS NUMA1, MNS1, ME1 CA4 1318/4885CA1 489/4885FAHD1 1433/4885
US-20080161560-A1 Process for Preparation of Calcium Salt of Rosuvastatin CACNA1C, CACNA1E, CACNA1S CA4 74/4885CA1 600/4885FAHD1 2259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.